Compare HTHT & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTHT | RGEN |
|---|---|---|
| Founded | 2005 | 1981 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.8B | 6.6B |
| IPO Year | 2010 | 1995 |
| Metric | HTHT | RGEN |
|---|---|---|
| Price | $45.07 | $122.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $56.60 | ★ $167.67 |
| AVG Volume (30 Days) | ★ 2.4M | 1.2M |
| Earning Date | 05-19-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.07% | N/A |
| EPS Growth | N/A | ★ 286.96 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $141,236,000.00 |
| Revenue This Year | $7.18 | $14.30 |
| Revenue Next Year | $6.71 | $14.52 |
| P/E Ratio | ★ $30.34 | $844.20 |
| Revenue Growth | N/A | ★ 35.10 |
| 52 Week Low | $30.42 | $100.99 |
| 52 Week High | $56.53 | $175.77 |
| Indicator | HTHT | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 41.89 | 54.31 |
| Support Level | $44.42 | $121.25 |
| Resistance Level | $45.90 | $131.53 |
| Average True Range (ATR) | 1.32 | 5.91 |
| MACD | 0.16 | 1.46 |
| Stochastic Oscillator | 60.11 | 74.44 |
H World Group Ltd a foremost, fast-growing multi-brand hotel group with international operations. The principal business activities of the Company are to develop and operate leased and owned, manachised and franchised hotels mainly in the PRC or PRC Mainland. The Group has two operating segments which are legacy Huazhu and legacy DH according to the way management intends to evaluate results and allocate resources within the Group. The majority of revenue comes from legacy Huazhu. The company has presence in Greater China and also Outside Greater China.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.